Russian radiopharmaceutical Radium chloride, 223Ra: first year of use in Russia. Real practice, efficacy, and safety profile. Possibilities of combination therapy

Cover Page

Cite item

Full Text

Abstract

The article presents current data on modern approaches to therapy of metastatic castration-resistant prostate cancer with focus on radionuclide methods using Radium chloride, 223Ra, and therapy of bone metastases. Data from real clinical practice of using Russian Radium chloride, 223Ra, manufactured by Prostor Pharma LLC to which Russian healthcare facilities gradually transitioned due to import phase-out in 2024–2025 are summarized. Russian Radium chloride, 223Ra manufactured by Russian company Prostor Pharma LLC is completely identical to the original drug in terms of composition, formulation, medical indications. Currently, 37 institutions work with this drug including 6 new centers opened in 2025 which allowed many patients to receive highly effective treatment in their region. According to the data from Russian clinics, the drug was mainly prescribed in the 2nd therapy line per clinical guidelines of the Association of Oncologists of Russia. However, in many patients the “therapeutic window” was missed which led to decreased number of courses and lower treatment efficacy.

The article presents a review of international and Russian clinical trials of the use of Radium chloride, 223Ra in therapy of metastatic castration-resistant prostate cancer, as well as data on its efficacy and safety.

About the authors

Valeriy V. Krylov

National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: krylov.mrrc@mail.ru
ORCID iD: 0000-0001-6655-5592

A.F. Tsyb Medical Radiological Research Center 

Russian Federation, 10 Marshala Zhukova St., Obninsk 249031

T. Yu. Kochetova

National Medical Research Radiological Center, Ministry of Health of Russia

Email: krylov.mrrc@mail.ru
ORCID iD: 0000-0002-7809-1059

A.F. Tsyb Medical Radiological Research Center 

Russian Federation, 10 Marshala Zhukova St., Obninsk 249031

A. I. Pronin

Teranostika

Email: krylov.mrrc@mail.ru
ORCID iD: 0000-0003-1632-351X
Russian Federation, premises 105,11 Erbanova St., Ulan-Ude 670000

References

  1. State of oncological care in Russia in 2024. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2025. 275 p. (In Russ.).
  2. James N.D., Tannock I., N’Dow J. et al. The Lancet Commission on prostate cancer: planning for the future. Lancet 2024;403(10432):1683–722. doi: 10.1016/S0140-6736(24)00651-2
  3. Prostate cancer. Clinical guidelines, 2021. (In Russ.).
  4. RUSSCO (Russian Society of Clinical Oncology). Practical guidelines, 2024. (In Russ.).
  5. Alyaev Yu.G., Krapivin A.A., Gusev I.V. et al. Radium 223 in treatment of bone metastases of castration-resistant prostate cancer: from mechanism of action to clinical practice. Urologiia = Urology 2023;(4):68–75. (In Russ.). doi: 10.29188/urology.2023.4.68-75
  6. Belousov A.S., Tyutin I.A., Krylov V.N. Radionuclide therapy in prostate cancer: modern approaches. Meditsinskaya radiologiya i radiatsionnaya bezopasnotst = Medical Radiology and Radiation Safety 2022;67(5):45–52. (In Russ.).
  7. Perepukhov V.M., Alekseev B.Ya., Nyushko K.M. Modern approaches to treatment of castration-resistant prostate cancer using targeted radionuclide therapy in patients with bone metastases. Onkourologiya = Cancer Urology 2024;20(4):132–8. (In Russ.). doi: 10.17650/1726-9776-2024-20-4-132-138
  8. Radiopharmaceutical “Radium chloride, 233Ra”. About the medication. Available at: https://prostorpharma.ru/preparaty/rflp-radiya-xlorid-223ra/ (In Russ.).
  9. Decision Chief State Sanitary Physician of the Russian Federation dated 27.03.2025 No. 6 “On approval of sanitary and epidemiologic rules and norms SanPiN 2.6.4115-25 “Sanitary and epidemiologic requirements for radiation safety of the population during circulation of sources of ionizing radiation”” (registered on 21.04.2025 No. 81916. Available at: http://publication.pravo.gov.ru/document/0001202504220013 (In Russ.).
  10. Gillessen S., Choudhury A., Saad F. et al. A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer: first results of EORTC-GUCG 1333/PEACE-3. ESMO Congress 2024. Abstract LBA1. Presented September 13, 2024.
  11. Kratochwil C., Rathke H., Giesel F.L. et al. Safety and efficacy of combined radium-223 and 177Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer: the RALU trial. J Nucl Med 2024. doi: 10.2967/jnumed.123.266841
  12. Wenzel M., Theissen L., Groener D. et al. Cancer control outcomes of Radium-223-pretreated Lutecium-177-PSMA Radioligand vs. Radium-223 naiive mCRPC patients. Eur J Nucl Med Mol Imaging 2025;52(11):4025–32. doi: 10.1007/s00259-025-07256-5
  13. Morris M.J., Castellano D., Herrmann K. et al. 177Lu-PSMA-617 versus alternative androgen receptor pathway inhibitors in patients with metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, open-label, randomised trial. Lancet 2024. doi: 10.1016/S0140-6736(24)01653-2
  14. Parker C., Nilsson S., Tombal B. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. doi: 10.1056/NEJMoa1213755
  15. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. doi: 10.1056/NEJMoa04072
  16. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: final overall survival results of a phase 3 randomised controlled trial (COU-AA-302). Lancet Oncol 2015;16(2):152–60. doi: 10.1016/S1470-2045(14)71205-7
  17. Beer T.M., Armstrong A.J., Rathkopf D. et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 2017;71(2):151–4. doi: 10.1016/j.eururo.2016.07.032
  18. Saad F., Clarke N.W., Oyа M. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24(10):1094–108. doi: 10.1016/S1470-2045(23)00382-0
  19. Kochetova T.Yu., Musabaev I.E., Krylov V.V., Tepper R.S. mCRPC radioligand therapy 177Lu-PSMA and 225Ac-PSMA: results of prospective single center study. Proceedings of the scientific and practical conference “Radiation and the body”, Obninsk, 11.2025. (In Russ.).
  20. Kostos L., Buteau J.P., Yeung T. et al. lphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med 2022;9:1059122. doi: 10.3389/fmed.2022.1059122

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Krylov V.V., Kochetova T.Y., Pronin A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.